Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. - Wikidata - awgldk - TriplyDB

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

http://www.wikidata.org/entity/Q35973288

about

Cardiovascular safety of anti-diabetic drugs Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice.Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.Impact of the 8-week Administration of Tofogliflozin for Glycemic Control and Body Composition in Japanese Patients with Type 2 Diabetes Mellitus Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.SGLT2 inhibitors in the management of type 2 diabetes.SGLT2 Inhibitors: Benefit/Risk Balance.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor.Medication use for the treatment of diabetes in obese individuals.From the past to future: from energy expenditure to energy intake to energy expenditure.Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date How Strongly Does Appetite Counter Weight Loss? Quantification of the Feedback Control of Human Energy Intake.Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.A safety evaluation of empagliflozin plus linagliptin for treating type 2 diabetes.Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.Effects of Ipragliflozin on Postprandial Glucose Metabolism and Gut Peptides in Type 2 Diabetes: A Pilot Study.Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.

P2860

Q26741082-A15BD303-51EC-46ED-BCF4-6AFAF7EDC4A4 Q28080114-DEA37BF1-6993-46DE-A137-32ED1792B09E Q30238791-ED4A972D-DA6E-42C9-8BEA-14854004716E Q30249371-DC702CB4-46D8-4465-9328-DECAA9A5A309 Q33625568-8A27B998-BB87-47AB-BF76-5E7DC6B7DFE7 Q33696974-C1B63849-CD61-4089-9044-43C7977DF5D2 Q33763305-A2AE0AD4-B79B-4F75-8FD3-0E4022D7C1DE Q33871321-93841E49-CD3A-4DD7-88F6-D3441221AA5C Q35952522-D9986EC0-561C-4E3E-A72D-4348907A49BF Q35957448-C7141403-C095-4D21-A9B3-FE9070FA784E Q37521103-D770897D-BB8F-4685-A64B-ADB0013E3965 Q37561260-9E3EAD5E-E600-41E7-8731-2E681FE5494F Q37588847-9208187E-CA38-4C1F-BA8F-C61BAF387C21 Q38592327-084AF0BC-F7B7-46A3-89B4-AB0BE55720A2 Q38619164-C1BF3365-6FA1-4AE7-BC21-1522D4DE1A58 Q38640778-3D80426D-9A54-48A3-8042-34C02D4FFA70 Q38783203-3A72C2CF-6F01-4BE3-A4B9-CDBA4D0CEBF0 Q38796262-6DEAE04F-29EA-4370-962D-582BF12B954B Q38827756-8193FBEF-E4DA-402F-BCE1-F542527CAFEF Q38857523-966C2368-1381-4284-8C13-23DE3C6CF778 Q38931842-FB5729BA-754A-41BA-AFAA-A5342933AEE5 Q38932322-63FC3F86-AB90-47E1-89CE-C007E74C57DE Q39000587-F77D9F21-3FAC-42AB-A7AA-19E9D1C21955 Q39006105-6CA41DF0-99EF-4F67-936D-4A36650B2719 Q39231122-211A6443-2DAE-4906-A7E3-68C316F826C3 Q39255188-6AEE19C5-9D62-4DBD-9162-1DCED7F22F83 Q39255963-E5398E99-8CFF-4306-88AB-246A807B28DC Q39304674-AE91DEA7-195B-485A-AB3F-AB49916214CD Q41066107-75C02B70-0A07-4DF8-9022-AEADD2884F65 Q41551599-FCA5513F-7AA7-4A65-AED5-3D143B0FF39C Q41717553-87354423-410C-48CA-A76C-7D8ECA3111DD Q42373168-FC4CCECE-410C-412F-9D64-889867DFAC22 Q42696416-B1A96268-CAB7-402B-AB3B-7ECE469F99A3 Q47115045-EC4A28F3-27BD-4D30-B4E3-86FCE152AD9A Q47766606-B2BE6D5A-3821-4D03-95B9-9ED700F95A04 Q47996942-1F223CA9-9DFE-443C-84DF-2EDF41BB74C6 Q48103374-854BB6DC-0F02-4172-9B59-609D33961DA5 Q48185851-1362C22F-CFE2-40B1-BEE5-DFA580E37095 Q48264817-BE61FEB9-FB50-4316-BF1B-5F609147D082 Q49963693-8F0748CD-7733-4E65-AE6F-3F30F93EF38F

P2860

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

http://www.wikidata.org/entity/Q35973288

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@ast

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@en

type

label

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@ast

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@en

prefLabel

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@ast

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@en

P1433

Q35973288-C1A98B88-7058-4785-8F07-D2306EAE57F9

P1476

Q35973288-C195F38D-F1C9-4282-859E-E116C47EA40D

P2093

Q35973288-0D58D035-D1A3-4F48-A2A3-2D4E5860A589

Q35973288-12328F6B-1021-41D4-A107-9B0BB2373CD3

Q35973288-544E8191-FE14-4126-97BD-234E81DBE2BC

Q35973288-5F12388D-3B72-4DB0-8098-F7F6A2C7D9C5

Q35973288-76DC31C5-4CD6-4DDC-9FA1-4BFED695B09D

Q35973288-91AC5DAF-7A65-4359-A09C-517AFCD56476

P2860

Q35973288-0814A88E-5916-468F-A9D6-ABAA89C02B9B

Q35973288-0935BA75-3A84-4FEB-8967-BDC556BAEB73

Q35973288-12A7E876-751F-42D0-9CA0-99E51FCBDC6C

Q35973288-1492F002-C432-4F70-A3E8-EB096B3AE180

Q35973288-16D493F1-696B-451F-B6A0-F4910BEFE90F

Q35973288-21081A12-645B-4DED-9637-13A12AB1D349

Q35973288-228B5EAC-AAB4-4819-85C6-2FEE1BCFD55E

Q35973288-2646D93B-C11E-416D-BD19-47044312C46F

Q35973288-28145836-2C6E-45BD-8887-1A5D49EC10F9

Q35973288-2B109654-8675-4BA4-8508-87BBB1D3AEA5

P304

Q35973288-BC717EEB-9D0E-4684-AFC0-0F78C6A63538

P31

Q35973288-AC145B30-73AB-41EC-A45C-1CD33ED131AD

P356

Q35973288-825BD12C-8231-4A1A-9128-77B0AED08993

P407

Q35973288-39F61760-77BC-4D1C-9577-8194DCBDDF9C

P433

Q35973288-1D6611B7-B9C2-4502-885C-40642BBC672A

P478

Q35973288-17FC5144-E9DF-4421-AFC9-406E75CF076E

P577

Q35973288-62828EFA-339B-4F57-A952-948D3C5798E4

P698

Q35973288-C7E18DE2-2565-40F1-BD4B-2951B4D1221D

P932

Q35973288-55DE132D-2621-4775-86E8-D1409DBEFF58

P356

P1433

P1476

Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.

@en

P2093

Arjun Sanghvi

http://www.w3.org/2001/XMLSchema#string

Ele Ferrannini

http://www.w3.org/2001/XMLSchema#string

Giulia Ferrannini

http://www.w3.org/2001/XMLSchema#string

Kevin D Hall

http://www.w3.org/2001/XMLSchema#string

Susanne Crowe

http://www.w3.org/2001/XMLSchema#string

Thomas Hach

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Water-Induced Thermogenesis

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Quantification of the effect of energy imbalance on bodyweight.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

P304

1730-1735

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC15-0355

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26180105

http://www.w3.org/2001/XMLSchema#string

P932

4542276

http://www.w3.org/2001/XMLSchema#string